



---

**FOR IMMEDIATE RELEASE**

**Obtained Imported Drug License for Levocarnitine Oral Solution in China**

Hong Kong, 15 July 2013 - Lee's Pharmaceutical Holdings Limited ("the Group") (Main Board Stock Code: 0950; Website: [www.leespharm.com](http://www.leespharm.com)) today announced that the Group has successfully obtained the Imported Drug License ("IDL") for marketing of Levocarnitine Oral Solution, in the People's Republic of China.

The Group has partnered with Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. ("Sigma-Tau"), an Italian pharmaceutical company, to market Carnitene® (Levocarnitine injection) exclusively in China since 2004. Subsequently, after successful completion of the required clinical study for the oral solution formulation of Levocarnitine in China, the Group has filed the application for its Imported Drug License in December 2010, and today successfully achieved the Imported Drug Licenses (IDL Nos. H20130455 for 1g & H20130454 for 2g) registered in the name of Sigma-Tau.

Levocarnitine oral solution with the active ingredient L-carnitine is significant for people with an increased risk of L-carnitine deficiency. It is used for therapy of carnitine deficiency disorders, the so-called primary and secondary levocarnitine deficiency. It compensates for levocarnitine losses that may be caused by various diseases and as side effects of certain forms of treatment.

"The approval of oral L-carnitine will complement to the current marketed injection formulations and boost the competitiveness of the Group's L-carnitine's franchise," said Dr. Benjamin Li, Chief Executive Officer of the Group. "Carnitene® injection has become the Group's leading product with growing market shares. This approval could serve as a catalyst for further growth of L-carnitine's franchise in China."

**About Lee's Pharmaceutical**

Lee's Pharmaceutical Holdings Limited is a research-based Hong Kong biopharmaceutical company with over 19 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharmaceutical is available at [www.leespharm.com](http://www.leespharm.com).

## FOR IMMEDIATE RELEASE

### **About Sigma-Tau**

Sigma-Tau is a leading, all Italian capital, International pharmaceutical group that invests in the research, development and marketing of innovative and effective treatments to improve human well-being and quality of life. Sigma-Tau Group has headquarters in Pomezia (Rome, Italy), and subsidiaries in France, Switzerland, the Netherlands, Belgium, Portugal, Germany, UK, India and with a production plant in Italy as well as in Spain and US (Indianapolis); with over 2000 employees and an extensive network of licensees worldwide achieved a global turnover of € 688 million in 2012.

The Sigma-Tau Group has invested, and continues to invest, a significant part of its revenue into research and development in order to identify innovative therapies to offer treatment also to people affected by rare diseases and/or diseases having a high clinical or social impact. Sigma-Tau carefully safeguards its own intellectual property: with 290 applications filed from 1998 to 2012. Out of approximately 20 R&D projects in the pipeline, are currently focused on the following therapeutic areas: Rare and Neglected Diseases, Oncology, Immuno-oncology, Biotechnology and at line extensions. Sigma-Tau R&D is also active in the Nutraceuticals and Medical Food. For further information about Sigma-Tau: Website: [www.sigma-tau.it](http://www.sigma-tau.it)

### **Safe Harbor Statement**

*The performance and the results of operation of Lee's during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's nor the Directors, employees or agents of Lee's assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialise or turns out to be incorrect.*

*For further information, please contact:*

*Vivian Fung*

*Tel: (852)2314-1282*

*Fax: (852)2314-1708*

*Email: [info@leespharm.com](mailto:info@leespharm.com)*